Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
5669664 | Reumatología Clínica | 2016 | 4 Pages |
Abstract
RTX use as second-line therapy after anti-TNF failure led to improvements in the efficacy and functional variables at 6 months, with no serious adverse events. These results were comparable to those observed in patients who used a second anti-TNF agent in the same clinical scenario.
Related Topics
Health Sciences
Medicine and Dentistry
Immunology, Allergology and Rheumatology
Authors
Vicenç Torrente-Segarra, Asunción Acosta Pereira, Rosa Morla, José Miguel Ruiz, Teresa Clavaguera, Ramon Figuls, Hector Corominas, Carme Geli, Rosa Roselló, Juan José de AgustÃn, Cayetano Alegre, Carolina Pérez, Angel GarcÃa,